




RealRate

PHARMACEUTICAL 2021

Tenax Therapeutics INC
Rank 141 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tenax Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tenax Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 175% points. The greatest weakness of Tenax Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 230% points.

The company's Economic Capital Ratio, given in the ranking table, is 317%, being 60% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	6,796
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,119
Liabilities, Non-Current	124
Other Assets	67
Other Compr. Net Income	19,703
Other Expenses	1.6
Other Liabilities	0
Other Net Income	18
Other Revenues	0
Property and Equipment	6.0
Research and Development	4,561
Selling, General and Administrative Expense	5,307

Output Variable	Value in 1000 USD
Assets	6,869
Liabilities	2,243
Expenses	9,870
Revenues	0
Stockholders Equity	4,626
Net Income	-9,851
Comprehensive Net Income	0.26
BaseVar	19,351
ECR before LimitedLiability	221%
Economic Capital Ratio	317%